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Abstract  
Dichotomous transformations for continuous outcomes are commonly used in practice. In this 
paper, we investigate dichotomisations for statistical inference about odds ratios in a situation where 
two underlying distributions from which independent samples are drawn are skewed and unknown. 
Under some mild conditions it is shown that a suitable choice of the cutpoint of a dichotomous 
transformation must lie within the range bounded by the two medians of the two underlying 
distributions, within which there exists a unique optimal cutpoint in terms of the asymptotic efficiency 
of point estimation and hypothesis testing. The issue of selecting a cutpoint is also linked to the 
choice amongst some existing nonparametric tests. 
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1. INTRODUCTION 
In clinical trials, when observed outcomes are continuous, two methods can be used to compare the 
treatment efficacy of a test drug against a placebo. One is to directly use the original continuous 
outcomes to draw statistical inference for the effect size defined as the standardised mean difference 
in a pre-specified efficacy measure. It is not unusual in clinical trials, however, particularly when the 
normality assumption of underlying distributions is questionable, for researchers to incorporate an 
alternative, where continuous outcomes are split into two categories and the treatment effect is 
characterised using an odds ratio. This approach is related to responder analysis in regulatory practice 
(see, e.g. [10] and [13]). Both approaches are quite common in practice. For example, Gotsche et al. 
[8] collects twelve studies on house mite control measures in the management of asthma for a 
systematic review, where seven studies report an effect size but the other five report an odds ratio. 
Abramson et al. [1] also find a mixture of approaches reported for immunotherapy in asthma. 
Clearly the latter approach, dichotomisation, has an advantage of clinical relevance in many 
applications where a clinical diagnosis of a disease by experiencing a level beyond a specific cutpoint 
is of most interest. Examples where a continuous variable is dichotomised because a range of the 
variable has distinct clinical significance include blood pressure, birth weight, respiratory function, 
blood glucose, olfactory function, and depression ([17]). As Ragland [17] has pointed out, it is 
common practice in clinical and epidemiologic studies to dichotomise continuous outcome variables, 
in part because therapeutic and policy decisions are usually based on thresholds and cutpoints rather 
than on continuous values.   
Further, from a statistical perspective, using the method of dichotomisations may also be beneficial 
in many circumstances. It is robust against outliers and the required assumptions about the underlying 
distributions are kept to a minimum [12]. One common criticism to dichotomisations is that it reduces 
statistical power. This is true under the normality assumption but becomes irrelevant in the general 
situation of non-Gaussian distributions.  
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When continuous outcomes are split into two categories, the resulting quantity of interest, such as 
the odds ratio for a treatment group compared to a control group and the difference in the two 
population proportions, depends on the chosen cutpoint. In practice, the cutpoint of a dichotomisation 
is usually selected on the basis of background knowledge, past experience, published studies or 
sometimes even in a relatively arbitrary manner. The selection of cutpoints in the absence of 
statistical guidance can, however, be potentially problematic. Friedman et al. [7, pp. 308] gives an 
example to demonstrate it can be misleading to apply a dichotomous transformation without a suitable 
cutpoint.  
In the Friedman example above, two therapies were administered to two groups of patients. The 
change in heart rate in beats per minute was measured for each patient before and after the treatments. 
Each of three cutpoints was used to split the data into two categories and a chi-square test and 
Fisher’s exact test were performed for each of the scenarios. It was found the significance levels 
change from significant (or not significant) to not significant (or significant) when different cutpoints 
were used. This example suggests that by manipulating the cutpoint, one can observe a significance 
level less than 0.05 when there does not really seem to be a difference.  
Since the choice of the cutpoint of a dichotomous transformation is important, considerable 
attention has been paid to this issue in both statistical and medical literatures. Ragland [17] and Deyi 
et al. [5] have investigated the issue of power reduction in dichotomisations when the outcomes of 
normal continuous variables are dichotomised. Not surprisingly, the power is shown to be lost to some 
extents when a dichotomous transformation of a normal variable is carried out. Selvin [18] and Kieser 
et al. [11] have further considered the relationships between dichotomisations and sample size 
determinations. Selvin [18] has calculated the ratio of required sample sizes with and without using a 
dichotomous transformation under the normality assumption. Kieser et al. [11] have investigated 
power and sample size determination when assessing the clinical relevance of trial results by 
responder analyses. The analysis in [11] is mainly on the basis of normality assumption but when the 
assumption of normal distributions is relaxed, a bootstrap procedure has been investigated.  
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In this paper we consider dichotomising continuous outcome variables under a general situation 
where the normality assumption is no longer valid. Rather, the underlying distributions are assumed to 
be skewed and unknown. We investigate dichotomous transformations of continuous outcomes for 
statistical inference about odds ratios and explore the links with some nonparametric methods, 
including Mood’s median test [16] and Mathisen’s test [15].  
An issue related to the problem investigated in this paper is to dichotomise a predictor variable 
when outcomes are binary (see, e.g. [6] and [14]). This paper, however, does not pursue this topic. We 
also note that there are extensive studies regarding dichotomisation of variables in the epidemiologic 
field (see e.g. [17] and [18]).  In this paper we focus on the context of clinical trials although the 
results also apply to epidemiologic studies.  
The following Section is devoted to the main results. Practical examples are examined in Section 3 
and concluding remarks are given in Section 4. Proofs for the theorems are given in the Appendix.  
 
2. MAIN RESULTS 
Consider a two-arm parallel group, placebo controlled clinical trial to investigate the efficacy of a 
test drug in the treatment of a disease. Eligible subjects are randomly allocated into test drug or 
placebo groups. Let ix ),...,1( mi   be continuous efficacy outcomes observed in the test drug group 
having a distribution of )( xxF  , and let jy ),...,1( nj   be continuous efficacy outcomes observed 
in the placebo group having a distribution of )( yyG  , where x  and y  are the medians of the two 
distributions so that 2/1)0()0( GF . 
Suppose )(xF  is known a priori to differ from )(xG  in the shape of distributions so that testing 
the difference between )( xxF   and )( yyG   is not of interest. The purpose of the analysis is 
rather to investigate whether the two populations have the same median, i.e. the statistical inference 
problem that we consider is a test of   
H01: yx       versus       H11: yx   , 
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with no specific shape assumptions on F and G.      
It is assumed the two unknown distributions )(xF  and )(xG  are absolutely continuous and 
possibly skewed. Let )(xf  and )(xg  denote the corresponding densities. To uniquely define a 
median, we suppose 0)0( f  and 0)0( g . However, it is not assumed the distributions have any 
specified functional forms. Clearly neither the t-test nor the Wilcoxon-Mann-Whitney test is suitable 
in this particular circumstance, for the former requires a normality assumption and the latter assumes 
a location shift is the sole distributional difference (see e.g. [20]).  
Now consider an alternative approach where binary coding is applied to split the continuous 
outcomes. Define a dichotomous transformation of a continuous variate z to be 

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


z
z
zT
 if      1
 if      0
)|( , 
where   is the cutpoint of the dichotomous transformation )|( zT  such that the continuous outcomes 
in each treatment group are split into two categories: favourable response and non-favourable 
response. Without loss of generality, suppose the category where observations are less than, or equal 
to, the cutpoint  , represents the favourable response. 
The dichotomous transformation )|( zT  is applied to the observations, ix ),...,1( mi   and 
jy ),...,1( nj  . Denote a  as the number of observations in the test drug group with a favourable 
response and anb  1 . Likewise, define c  and d  for the placebo group, as displayed in Table 1.  
 
Table 1: Outcomes by Applying a Dichotomous Transformation 
   (favourable)   (unfavourable) Total 
Test drug a  b  m 
Placebo c d  n 
 
 
In practice, the logarithm of an odds ratio is usually estimated by )/ln( bcad , and the 
corresponding variance is estimated by the Woolf’s method: dcbaV /1/1/1/1ˆ   (see, e.g. [9]).  
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The null hypothesis for the detection of whether there is a treatment difference between the test 
drug and placebo is:   
H02: 0)ln( OR    versus    H12: 0)ln( OR , 
where )ln(OR  is the logarithm of the odds ratio when a dichotomous transformation )|( zT  is 
applied to split the outcomes:  
)()}(1{
)}(1){(
ln)ln(
yx
yx
GF
GF
OR




 . When splitting data into two 
categories, it is important to raise the question: is testing H02 equivalent to testing H01?  
 
THEOREM 1. Suppose two distributions )( xxF   and )( yyG   are absolutely continuous with 
2/1)0()0( GF . Their densities )( xxf   and )( yyg   satisfy 0)0( f  and 0)0( g . If the 
cutpoint   of a dichotomous transformation )|( zT  is taken anywhere between x  and y , then 
yx    if and only if 0)ln( OR .  
 
Theorem 1 shows that if the cutpoint of a dichotomous transformation is taken somewhere 
between the two medians of the underlying distributions, then it is guaranteed that testing the null 
hypothesis H01 is equivalent to testing H02.  
Next, we show that the choice of a cutpoint relates to the asymptotic efficiency of point 
estimation and hypothesis testing. We first note that when the sample sizes become large, counts a 
and c approach to their expected frequencies, )( xmF    and )( ynG    respectively. 
Consequently, the estimated variance approaches 
)}(1/{)(/[ xx FrFrV   nGG yy /)}](1/{1)(/1   , 
where it is assumed rmn / , where  r0 , as sample sizes approach infinity.  
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THEOREM 2. Suppose densities )( xxf   and )( yyg   are log-concave and continuously 
differentiable. Then there exists a cutpoint *  lying between x  and y  such that the asymptotic 
variance of )/ln( bcad  attains the global minimum. 
 
  Furthermore, it is immediate from Theorem 2 that we have 
 
COROLLARY 1. Under the conditions of Theorem 2, if the cutpoint   of a dichotomous 
transformation )|( zT  lies between x  and y , then the asymptotic variance of )/ln( bcad  attains 
the global minimum under H02. 
 
Theorem 2 ensures the existence of the optimal cutpoint that leads to the asymptotically most 
efficient estimate of )ln(OR  among all dichotomous transformations )|( zT . It, however, does not 
indicate, except for a range, where exactly this optimal cutpoint lies. From the proof of Theorem 2 the 
location of the optimal cutpoint relies on the specific forms of the underlying distributions. In practice, 
two reasonable choices for cutpoints can be: (a) the median of the combined sample; and (b) a 
weighted midway point of the two medians, )/()(0 xyyxxy   , where x  and y  are the 
corresponding inter-quartile ranges of the two underlying distributions. For the special case 
investigated in [11] where )( xxF   and )( yyG    are two normal distributions having equal 
variance with equal sample sizes, it can be seen that 0  satisfies the first-order condition in the proof 
of Theorem 2 in the Appendix so that 0  is an optimal cutpoint for that particular circumstance.  
In practice, the z-test is frequently used to test the null hypothesis H02 when sample sizes are not 
small [9]. Not surprisingly, the power of the z-test relies on the choice of the cutpoint  . In fact, it is 
easy to find that the power of the z-test is a strictly decreasing function of Vˆ . Hence, asymptotically 
the power of the z-test attains maximum, i.e. the type II error is kept to a minimum, if the optimal 
cutpoint *  indicated in Theorem 2 is used in a dichotomous transformation. 
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COROLLARY 2. Under the conditions of Theorem 2, applying the dichotomous transformation with 
the optimal cutpoint *  leads to a maximum power of the z-test for testing H02 versus H12 among all 
dichotomisations )|( zT . 
 
Remark: The conclusions drawn in Theorem 2 and Corollaries 1 and 2 do not rely on any specific 
forms of underlying distributions. Rather, they can be anyone in the log-concavity (also called 
strongly unimodal) distribution family. The assumption of log-concavity is widely used in statistical 
literature. Mathematically, this assumption is critical to guarantee a global minimum of the asymptotic 
variance. From a practical perspective, the log-concavity distribution family includes many commonly 
used unimodal distributions, such as normal, uniform, logistic, exponential, extreme values, gamma 
with shape parameter greater than or equal to 1, Weibull with the shape parameter greater than or 
equal to 1 (see [2] and [3] for details).  
Before concluding this section, we note that selecting a cutpoint of a dichotomous transformation 
for testing H02 is linked to the choice amongst nonparametric tests, including Mood’s median test [16] 
and Mathisen’s test [15], where the former method incorporates a cutpoint of the median of the 
combined sample, and the latter method has a cutpoint of x . For either method, the favourable and 
non-favourable responses are counted for each treatment group, as displayed in Table 1 (see, e.g. [20, 
pp. 86]). The null hypothesis H01 is then tested using a hypergeometric distribution under H01, or 
based on a normal approximation when sample sizes are not small. It is worth noting that the median 
0  of the distribution, )()}1/(1{)( xxFrxH   )()}1/({ yxGrr  , from which the combined 
sample is drawn lies between x  and y , although, in general, it is not the optimal cutpoint. 
Theoretically selecting any other percentile of H(x) lying between x  and y  leads to a non-
parametric test. However, without knowledge of the shapes of the two underlying distributions F(x) 
and G(x), it is hard to justify that such a choice is better than the Mood’s median test.  
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3. PRACTICAL EXAMPLES 
 
To illustrate the results obtained in the previous section, we consider an example investigated in 
[4], where the data comprise the average capillary densities for both feet for 19 healthy subjects and 
23 ulcer patients. To test if the population of ulcer patients has the same mean value as the healthy 
population, Bland [4] performs the t-test, resulting in a calculated t-value of 5.08. The null hypothesis 
was thus rejected at the significance level of 1 %. 
 We applied dichotomous transformations to the capillary density data to investigate the impact of 
the choice of a cutpoint. Totally 100 cutpoints were selected between the median of the ulcerated 
patient group, 22.5, and the median of the healthy group, 34.5, with a constant increment step of 0.12. 
The weighted midway point of the two sample medians is 0ˆ 28.1 and the median of the combined 
sample is 0ˆ 27.25.   
Figure 1 gives the plot of the estimated standard deviation versus cutpoint. It is noted that an 
appropriate cutpoint should be somewhere between 27 and 28.5, where the corresponding estimated 
standard deviation is much smaller than that in the remaining area. In particular, a cutpoint less than 
27 or greater than 29 results in a much larger value of the estimated standard deviation, demonstrating 
a very poor quality of the estimated log odds ratio. 
 
Fig.1: Estimated standard deviation versus cutpoint 
(Figure 1 is about here) 
 
Figure 2 displays a plot of p-value versus cutpoint when the z-test was performed to test the null 
hypothesis H02. Choosing a cutpoint in the interval [27, 29] has a maximum chance to give a result 
being consistent with that obtained by the t-test for the continuous outcomes. In this example both 
0ˆ 28.1 and 0ˆ 27.25 are suitable choices. 
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Fig.2: The p-value versus cutpoint 
(Figure 2 is about here) 
 
Returning to the heart rate data mentioned in Section 1, the two sample medians coincide so the 
only reasonable choice for the cutpoint is the median per se. This leads to the optimal estimate of OR 
which is equal to 1, and a result for hypothesis testing for dichotomised observations which is 
consistent with a t-test for the raw measures carried out in [7].  
 
4. CONCLUDING REMARKS 
This paper investigates dichotomisations for continuous outcomes. It is motivated by the example 
in [7] where the choice of a cutpoint could be misleading by manipulating the cutpoint.  
Overall, dichotomisations are very useful in clinical trials due to its clinical relevance [12] but it is 
controversial from a statistical perspective. As demonstrated in previous studies such as [5], [11], [17] 
and [19], dichotomisations reduce statistical power because some of the information contained in the 
underlying distribution is discarded.  We share the concerns raised in these studies and believe that, 
from a statistical perspective, data should not be dichotomised when they are approximately normally 
distributed.  
In practice, however, it is not unusual that true distributions are unknown and robustness is a big 
issue. In these circumstances dichotomisations can play an important role where most of the criticisms 
on dichotomisations become irrelevant because the efficiencies in these criticisms were usually 
calculated under the normality (or symmetry) assumption in the first place.  
In this paper we have investigated the general situation of non-Gaussian distributions. Our study 
shows that a suitable cutpoint of a dichotomous transformation must lie within a certain range 
bounded by the two medians of the two independent samples. Further, within this range, there exists a 
unique optimal cutpoint in terms of point estimation and hypothesis testing. We have also linked the 
issue of selecting a cutpoint to the choice of a nonparametric test. Consequently we have provided 
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statistical guidance for the choice of cutpoints of dichotomisations from the perspectives of estimation 
and hypothesis testing of odds ratios. We hope this is helpful for researchers in defining 
dichotomisations which are both statistically justified and clinically relevant.   
 
APPENDIX 
Proof of Theorem 1. Without loss of generality, we suppose yx   . Since the cutpoint   lies 
between the two medians, we have  
2/1)(  xF        and      2/1)(  yG  .    (A1) 
Now if 0)ln( OR , then )()( yx GF   . From (A1) we obtain  )()( yx GF   =1/2. 
Since 0)0( f  and 0)0( g , we have yx   . On the other hand, if yx   , then x   and 
y   since   lies between the two medians. Hence, we have 0)ln( OR . This completes the proof. 
 
LEMMA. Suppose that )(xu  is a log-concave and differentiable density. Let )(xU  be the 
corresponding cumulative distribution. Then )](1/[1)(/1)( xUxUxJ   is convex,  
Proof. By some algebra we obtain 
          ])}(1/{1)(/1)[(/
33222 xUxUxudxJd   
32 )}(/{)]()()([ xUxUxuxu  32 )}(1/{)}](1){()([ xUxUxuxu  , 
where dxxduxu /)()(  . Since )(xu  is log-concave, from Lemma 2 in [2] we have  
0)()()(2  xUxuxu   and    0)}(1){()(2  xUxuxu , 
which lead to 0/ 22 dxJd . This completes the proof.  
 
Proof of Theorem 2. Without loss of generality, we suppose yx   . It is easy to find that  
}))(())(1){(([/ 22   xxx FFrfddV   
nGGg yyy /}]))(())(1){((
22    . 
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Let 0 xy   and denote ddV /  as )(h . Then we have 
nGGgh x /])}({)}(1)[{()(
22    . 
Since 2/1)( G , we obtain 0)( xh  . Similarly we can show 0)( yh  . Hence, there exists 
],[* yx    such that 0*)( h . From the Lemma above, V attains the global minimum at * . This 
completes the proof. 
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Fig.1: Estimated standard deviation versus cutpoint 
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Fig.2: The p-value versus cutpoint 
 
